Supplemental thiamine for the treatment of acute heart failure syndrome: a randomized controlled trial

Table 5 Morbidity and Mortality outcomes by thiamine supplementation

Measure	Control	Treatment	p-value (model)
Length of Stay (mean days)
Unadjusted (n = 117)*	5 (4–6)	5 (4–6)	0.71
30-Day Rehospitalization (%)
Unadjusted (n = 107)*	20.1 (9.2–31.0)	26.2 (15.1–37.4)	0.45
^**Mortality (%)
n = (111)	1.9 (−1.8 to 5.5)	3.5 (−1.4 to 8.4)	1.00

Estimates include 95%Confidence Intervals.. P-values are from the treatment group indicator in the model
^*Includes design variables: site, diabetes medication (self-report) and NT-proBNP quartile. Deceased patients excluded. (n = 3)
^**Due to the small number of events (Control n = 1, Treatment n = 2) modeling was not conducted. P-value from Fisher exact test

ISSN: 2662-7671